Page last updated: 2024-11-04

kynurenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Kynurenic acid is a tryptophan metabolite that acts as an antagonist of the glycine site of the NMDA receptor. It is also an antagonist of the α7 nicotinic acetylcholine receptor. Kynurenic acid is produced in the liver and brain and is present in the cerebrospinal fluid. It has been implicated in a number of neuropsychiatric disorders, including schizophrenia, depression, and Alzheimer’s disease. Its synthesis is catalyzed by the enzyme kynurenine aminotransferase (KAT). Kynurenic acid is an important neuroprotective agent, and it has been shown to protect neurons from excitotoxicity, a process that contributes to the death of neurons in a number of neurodegenerative diseases. It has been studied extensively for its potential therapeutic effects in neurodegenerative diseases and other disorders. However, it is also being investigated for its possible role in the pathogenesis of certain diseases and the development of new drugs.'

Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3845
CHEMBL ID299155
CHEBI ID18344
SCHEMBL ID22979
MeSH IDM0012091

Synonyms (155)

Synonym
nsc 58973
einecs 207-751-5
ccris 4428
smr000112310
MLS002172436
EN300-13998
HMS3266C13
BB 0262293
STL294769
STL301826
gtpl2918
CHEBI:18344 ,
4-hydroxy-2-chinolincarbonsaeure
kynurensaeure
DIVK1C_000309
KBIO1_000309
AE-641/00585057
EU-0100716
kynurenic acid, >=98%
4-hydroxyquinaldinic acid
2-quinolinecarboxylic acid, 4-hydroxy-
nsc-58973
kynuronic acid
quinaldic acid, 4-hydroxy-
4-hydroxyquinoline-2-carboxylic acid
kinurenic acid
quinurenic acid
NSC58973 ,
4-hydroxyquinaldic acid
SPECTRUM_001116
OPREA1_032085
lopac-k-3375
NCGC00015581-01
NCGC00024505-01
tocris-0223
BSPBIO_002980
LOPAC0_000716
BIOMOL-NT_000229
SMP1_000172
SPECTRUM5_001318
kyna
492-27-3
kynurenic acid
C01717
4-hydroxy-2-quinolinecarboxylic acid
kynurenate ,
PDSP1_000132
NCGC00024505-07
NCGC00024505-04
NCGC00024505-03
KBIO2_004164
KBIOGR_001327
KBIO3_002200
KBIO2_006732
KBIO2_001596
KBIOSS_001596
SPECTRUM3_001390
SPECTRUM4_000814
NINDS_000309
SPECTRUM2_001342
SPBIO_001523
SPECTRUM1500688
PDSP2_000131
IDI1_000309
BPBIO1_001350
NCGC00024505-02
NCGC00024505-06
NCGC00024505-05
4-oxo-1h-quinoline-2-carboxylic acid
K-8900
NCGC00015581-03
6F535706-B297-4930-A3FC-7A2823830118
K 3375
inchi=1/c10h7no3/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9/h1-5h,(h,11,12)(h,13,14)
NCGC00015581-09
hczhheifkropdy-uhfffaoysa-
AKOS000277721
AKOS000118368
CHEMBL299155 ,
transtorine
BMSE000410
HMS500P11
4-hydroxy-2-quinolincarboxylic acid
H0303
HMS1921C20
HMS1736A10
bdbm81975
nsc_5280455
cas_492-27-3
HMS3262O13
1,4-dihydro-4-oxoquinoline-2-carboxylic acid
13593-94-7
KYA ,
4-oxo-1,4-dihydroquinoline-2-carboxylic acid
HMS2269G22
S4719
CCG-39280
NCGC00015581-05
NCGC00015581-02
NCGC00015581-04
NCGC00015581-08
NCGC00015581-07
NCGC00015581-06
FT-0670692
FT-0683827
unii-h030s2s85j
h030s2s85j ,
LP00716
4-oxo-1,4-dihydro-quinoline-2-carboxylic acid
2-carboxy-4-hydroxyquinoline
4-hydroxy-quinoline-2-carboxylic acid
BBL027606
SCHEMBL22979
kynurenic acid [mi]
tox21_500716
NCGC00261401-01
4-hydroxyquinolinium-2-carboxylate
CS-W020664
HB0362
mfcd00006753
DTXSID8075417
mfcd03197717
GS-3763
Z94602408
J-006786
SR-01000075455-3
SR-01000075455-1
sr-01000075455
HY-100806
4-hydroxy-quinaldate
4-hydroxyquinaldinate
4-hydroxy-quinaldic acid
4-hydroxyquinaldate
DB11937
quinurenic acid|kynurenate
HMS3675C03
kynurenic-acid
bdbm50233945
HMS3411C03
Q642217
AMY18102
SDCCGSBI-0050694.P003
NCGC00015581-14
HMS3885D20
A847277
S12153
1,4-dihydro-4-oxoquinoline-2-carboxylicacid
SB67643
SB67494
4-hydroxyquinoline-2-carboxylicacid
HY-W110662
BK166244
CS-0168103
4-oxo-1,4-dihydroquinoline-2-carboxylicacid
SY152524

Research Excerpts

Overview

Kynurenic acid (KYNA) is a metabolite of tryptophan (TRP) It is a broad-spectrum antagonist of excitatory amino acid receptors. It may serve as a protective agent in neurological disorders.

ExcerptReferenceRelevance
"Kynurenic acid (KYNA) is an endogenous product of the tryptophan metabolism and, as a broad-spectrum antagonist of excitatory amino acid receptors, may serve as a protective agent in neurological disorders."( Synthesis and biological effects of some kynurenic acid analogs.
Demeter, I; Farkas, T; Fülöp, F; Gellért, L; Kis, Z; Klivényi, P; Marosi, M; Nagy, K; Plangár, I; Szatmári, I; Toldi, J; Tuka, B; Varga, D; Vécsei, L; Zádori, D, 2011
)
1.36
"Kynurenic acid (KYNA) is an endogenous neuroprotective agent of increasing importance. "( KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect.
Lőrinczi, B; Szatmári, I, 2021
)
2.06
"Kynurenic acid (KYNA) is a metabolite of tryptophan (TRP). "( Increased plasma level of kynurenic acid in drug-free patients with first-episode schizophrenia compared to patients with chronic schizophrenia and healthy controls: preliminary data.
Ding, W; Li, H; Ning, Y; Wang, R; Wu, F; Zhou, S, 2022
)
2.46
"Kynurenic acid (KYNA) is an important bio-active product of tryptophan metabolism. "( Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases.
Liu, J; Song, Z; Zhang, XD; Zhen, D, 2022
)
3.61
"Kynurenic acid is a by-product of tryptophan metabolism in humans, with abnormal levels indicative of disease. "( Naphthalene-functionalized resorcinarene as selective, fluorescent self-quenching sensor for kynurenic acid.
Beyeh, NK; Haddad, A; Karle, A; Sabbagh, N; Szczęśniak, MM; Taimoory, SM; Trant, JF; Trivedi, E; Twum, K, 2022
)
2.38
"Kynurenic acid (KYNA) is a neuroactive metabolite of the kynurenine pathway of tryptophan degradation."( Binge-like mephedrone treatment induces memory impairment concomitant with brain kynurenic acid reduction in mice.
Budzynska, B; Kaszubska, K; Kotlinska, JH; Lemieszek, MK; Marciniak, S; Marszalek-Grabska, M; Rzeski, W; Turski, WA; Winiarczyk, S; Zakrocka, I, 2022
)
1.67
"Kynurenic acid (KA) is a tryptophan metabolite in the kynurenine pathway."( Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization
Cheng, C; Cong, J; He, H; Kang, G; Li, J; Sun, T; Wang, X; Xie, Q; Xie, R; Yin, W; Zhao, X, 2022
)
2.89
"Kynurenic acid is a common differential metabolite that could be used as a candidate for both diagnosis and prognosis for septic patients with cardiac dysfunction."( Untargeted metabolomic profiling of sepsis-induced cardiac dysfunction.
Cao, Y; Fang, C; Han, X; Huang, J; Jing, Y; Liu, Z; Ma, W; Pei, Y; Xiao, W, 2023
)
1.63
"Kynurenic acid (KYNA) is an endogenous molecule, which is a non-selective antagonist of ionotropic glutamate receptors and has been found to have neuroprotective activity. "( Convenient One-Pot Synthesis of Kynurenic Acid Ethyl Ester and Exploration to Direct Synthesis of Neuroprotective Kynurenic Acid and Amide Derivatives.
Ambatwar, R; Datusalia, AK; Khatik, GL; Verma, S, 2023
)
2.64
"Kynurenic acid (KYNA) is an endogenous tryptophan metabolite exerting neuroprotective and anticonvulsant properties in the brain. "( Kynurenic acid and cancer: facts and controversies.
Plech, T; Turski, WA; Walczak, K; Wnorowski, A, 2020
)
3.44
"Kynurenic acid (KYNA) is a neuroactive metabolite of tryptophan. "( Chronic dietary supplementation with kynurenic acid, a neuroactive metabolite of tryptophan, decreased body weight without negative influence on densitometry and mandibular bone biomechanical endurance in young rats.
Dobrowolski, P; Donaldson, J; Kuc, D; Lamorski, K; Mielnik-Błaszczak, M; Muszyński, S; Paluszkiewicz, P; Parada-Turska, J; Smolińska, K; Świetlicka, I; Tomaszewska, E, 2019
)
2.23
"Kynurenic acid (KYNA) is an L-tryptophan metabolite with neuromodulatory activities, regulating the release of neurotransmitters such as glutamate, dopamine (DA), and acetylcholine (Ach). "( Antidepressant-like effects of kynurenic acid in a modified forced swim test.
Bohár, Z; Martos, D; Tanaka, M; Telegdy, G; Vécsei, L, 2020
)
2.29
"Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). "( Kynurenic Acid Levels are Increased in the CSF of Alzheimer's Disease Patients.
Antequera, D; Arjona, JAM; Bartolome, F; Bisa, AL; Carro, E; Domínguez, E; González-Sánchez, M; Jiménez, J; Llamas-Velasco, S; Marco, MP; Martín, AH; Munain, AL; Narváez, A; Pérez-Martínez, DA; Rodríguez-Núñez, M; Villarejo-Galende, A, 2020
)
3.44
"Kynurenic acid (KYNA) is a compound derived from the tryptophan catabolic pathway. "( An efficient method for production of kynurenic acid by Yarrowia lipolytica.
Kocki, T; Rakicka-Pustułka, M; Rymowicz, W; Turski, W; Wróbel-Kwiatkowska, M, 2020
)
2.27
"Kynurenic acid is a metabolite in the kynurenine pathway that has been widely accepted as being a major mechanism in MDD."( Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
Erabi, H; Fuchikami, M; Kang, D; Kato, TA; Kurata, A; Okada, G; Okamoto, Y; Setoyama, D; Shibasaki, C; Takamura, M; Yamawaki, S; Yoshino, A, 2020
)
2.72
"Kynurenic acid (KA) is a tryptophan metabolite that has been shown to exert anti-inflammatory effects in macrophages and endothelial cells."( Endogenous metabolite, kynurenic acid, attenuates nonalcoholic fatty liver disease via AMPK/autophagy- and AMPK/ORP150-mediated signaling.
Abd El-Aty, AM; Hong, SA; Jeong, JH; Jung, TW; Kim, MJ; Kim, TJ; Pyun, DH, 2021
)
1.65
"Kynurenic acid is an endogenous modulator of ionotropic glutamate receptors and a suppressor of the immune system. "( Sensitivity of Rodent Microglia to Kynurenines in Models of Epilepsy and Inflammation In Vivo and In Vitro: Microglia Activation is Inhibited by Kynurenic Acid and the Synthetic Analogue SZR104.
Dulka, K; Földesi, I; Fülöp, F; Gulya, K; Kata, D; Lajkó, N; Mátyás, A; Mihály, A; Szabó, M; Vécsei, L, 2020
)
2.2
"Kynurenic acid (KYNA) is a potential biomarker candidate for this purpose."( Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer's Disease.
Marco, MP; Marrugo-Ramírez, J; Mir, M; Rodríguez-Núñez, M; Samitier, J, 2021
)
2.79
"Kynurenic acid (KYNA) is a KP metabolite synthesized by kynurenine aminotransferases (KATs) from its biological precursor kynurenine and acts as an endogenous antagonist of N-methyl-D-aspartate and α7-nicotinic acetylcholine receptors."( Prenatal Kynurenine Elevation Elicits Sex-Dependent Changes in Sleep and Arousal During Adulthood: Implications for Psychotic Disorders.
Baratta, AM; Ditty, AL; Milosavljevic, S; Mong, JA; Pocivavsek, A; Rentschler, KM; Wagner, NTJ; Wright, CJ, 2021
)
1.34
"Kynurenic acid (KYNA) is an endogenous metabolite of tryptophan produced by kynurenine aminotransferase II (KAT II) in the brain."( Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications.
Jóźwiak, K; Kocki, T; Targowska-Duda, KM; Turski, WA; Wnorowski, A; Zakrocka, I, 2017
)
1.18
"Kynurenic acid (KYNA) is a neuroactive metabolite of tryptophan known to modulate a number of mechanisms involved in neural dysfunction. "( Kynurenic Acid Prevents Cytoskeletal Disorganization Induced by Quinolinic Acid in Mixed Cultures of Rat Striatum.
Biasibetti-Brendler, H; Ferreira, F; Pessoa-Pureur, R; Pierozan, P; Schmitz, F; Wyse, ATS, 2018
)
3.37
"Kynurenic acid (KA) is a tryptophan (Trp) metabolite that is synthesised in a branch of kynurenine (KYN) pathway. "( Kynurenine aminotransferase activity of Aro8/Aro9 engage tryptophan degradation by producing kynurenic acid in Saccharomyces cerevisiae.
Chaleckis, R; Ohashi, K; Takaine, M; Wheelock, CE; Yoshida, S, 2017
)
2.12
"Kynurenic acid (KYNA) is an antagonist to the α-7nACh and NMDA receptors."( Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Koola, MM, 2018
)
1.4
"Kynurenic acid (KYNA) is a biologically active metabolite of tryptophan exerting action on several receptors located in the brain and periphery. "( Fate and distribution of kynurenic acid administered as beverage.
Dukowski, P; Kocki, T; Pelak, J; Plech, T; Turska, M; Turski, MP; Turski, W, 2018
)
2.23
"Kynurenic acid (KYNA) is a metabolite of tryptophan formed enzymatically along kynurenine pathway in bacteria, fungi, plants and animals. "( Presence of kynurenic acid in alcoholic beverages - Is this good news, or bad news?
Dabrowski, W; Dobrowolski, A; Kocki, T; Muszyńska, B; Paluszkiewicz, M; Pelak, J; Plech, T; Rutyna, R; Terlecka, P; Turska, M; Turski, MP, 2019
)
2.34
"Kynurenic acid (KYNA) is an astrocyte-derived non-competitive antagonist of the α7 nicotinic acetylcholine receptor (α7nAChR) and inhibits the NMDA receptor (NMDAR) competitively. "( Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo.
Antonelli, T; Beggiato, S; Ferraro, L; Fuxe, K; Schwarcz, R; Tanganelli, S; Tomasini, MC, 2013
)
3.28
"Kynurenic acid (KYN) is a metabolite of tryptophan and is involved in various neurological disorders. "( Glutamatergic activities in neonatal rat spinal cord heterogeneously regulate single-fiber splanchnic nerve discharge.
Chiang, CH; Fan, YP; Ho, CM; Lee, CM; Su, CK, 2013
)
1.83
"Kynurenic acid is a tryptophan metabolite that is synthesized and released in the brain by astrocytes and acts as an antagonist of nicotinic acetylcholine receptors and N-methyl-d-aspartate glutamate receptors, both of which are critically involved in cognition as well as neural plasticity and brain development. "( The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.
Bucci, DJ; Iaccarino, HF; Suckow, RF; Xie, S, 2013
)
2.11
"Kynurenic acid (KYNA) is an endogenous negative allosteric modulator of α7nAChRs."( Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid.
Barnes, C; Bergman, J; Ferré, S; Fratta, W; Goldberg, SR; Justinova, Z; Kangas, BD; Mascia, P; Panlilio, LV; Parashos, A; Pistis, M; Redhi, GH; Scherma, M; Schwarcz, R; Secci, ME; Solinas, M; Tanda, G; Wu, HQ; Zara, T, 2013
)
1.33
"Kynurenic acid (KYNA) is a metabolite of kynurenine possessing anti-inflammatory, anti-oxidative and pain reliving properties."( Kynurenic acid content in anti-rheumatic herbs.
Majdan, M; Parada-Turska, J; Rajtar, G; Turska, M; Zgrajka, W, 2013
)
2.55
"Kynurenic acid (KYNA) is a tryptophan metabolite that acts in the brain as an endogenous antagonist at multiple receptors, including glutamate and α7 nicotinic acetylcholine receptors. "( A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats.
Gritton, H; Johnson, DE; Koshy Cherian, A; Kozak, R; Sarter, M; Young, D, 2014
)
1.85
"Kynurenic acid (KYNA) is a side-stream product of the kynurenine metabolic pathway that plays a controversial role in malignancies either enabling escape of malignant cells from immune surveillance or exerting antiproliferative effect on cancer cells, and is associated with differences in invasiveness related to metastatic spread to lymph nodes in lung cancer. "( Utility of kynurenic acid for non-invasive detection of metastatic spread to lymph nodes in non-small cell lung cancer.
Kocki, J; Kocki, T; Patel, S; Sagan, D, 2015
)
2.25
"Kynurenic acid (KYNA) is a neuroactive metabolite that interacts with NMDA, AMPA/kainate and alpha 7 nicotinic receptors. "( The inimitable kynurenic acid: the roles of different ionotropic receptors in the action of kynurenic acid at a spinal level.
Bohar, Z; Horvath, G; Kekesi, G; Pardutz, A; Petrovszki, Z; Safrany-Fark, A; Tar, L; Tuboly, G; Vecsei, L, 2015
)
2.21
"Kynurenic acid (KYNA) is a small molecule derived from tryptophan when this amino acid is metabolized through the kynurenine pathway."( Ischemic preconditioning protects neurons from damage and maintains the immunoreactivity of kynurenic acid in the gerbil hippocampal CA1 region following transient cerebral ischemia.
Ahn, JH; Bae, EJ; Chen, BH; Cho, GS; Cho, JH; Choi, SY; Kim, IH; Kim, YM; Lee, JC; Park, J; Park, JH; Shin, BN; Tae, HJ; Won, MH, 2015
)
1.36
"Kynurenic acid (KYNA) is an endogenous antagonist of NMDA receptors which has been demonstrated under experimental conditions to be neuroprotective."( Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.
Majláth, Z; Toldi, J; Török, N; Vécsei, L, 2016
)
1.52
"Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect."( Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion.
Csáti, A; Edvinsson, L; Fülöp, F; Tajti, J; Toldi, J; Vécsei, L; Warfvinge, K, 2015
)
2.58
"Kynurenic acid (KYNA) is an end stage product of tryptophan metabolism with a variety of functions in the human body, both in the central nervous system (CNS) and in other organs. "( Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms.
Kwiecień, JM; Langner, E; Lemieszek, MK; Rajtar, G; Rzeski, W; Turski, WA, 2017
)
3.34
"Kynurenic acid (KYNA) is an endogenous substance produced on the kynurenine pathway which is primarily known for its neuroactive properties. "( Effect of feed supplementation with kynurenic acid on the morphology of the liver, kidney and gills in rainbow trout (Oncorhynchus mykiss Walbaum, 1792), healthy and experimentally infected with Yersinia ruckeri.
Kaczorek, E; Małaczewska, J; Mikiewicz, M; Schulz, P; Siwicki, AK; Szarek, J; Terech-Majewska, E; Wójcik, R, 2017
)
2.17
"Kynurenic acid (KYNA) is a neuroactive metabolite of tryptophan formed in the brain and in the periphery, known to block ionotropic glutamate receptors and α7 nicotinic receptors, and to act as a ligand of G protein-coupled GPR35 receptors and human aryl hydrocarbon (AHR) receptors. "( [The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].
Flis, M; Kandefer-Szerszeń, M; Karakuła-Juchnowicz, H; Krukow, P; Morylowska-Topolska, J; Szymona, K; Urbańska, A; Urbańska, EM; Zdzisińska, B, 2016
)
2.39
"Kynurenic acid (KYNA) is an endogenous antagonist of N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors that is derived from astrocytes as part of the kynurenine pathway of tryptophan degradation. "( Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.
Caravaggio, F; Chakravarty, MM; Chung, JK; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Kim, J; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2017
)
3.34
"Kynurenic acid (KYNA) is an endogenous blocker of alpha7 nicotinic receptors and a glutamate-receptor antagonist, preferentially blocking N-methyl-D-aspartate (NMDA) receptors."( Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area.
Engberg, G; Erhardt, S; Linderholm, KR; Nilsson-Todd, LK; Schwieler, L, 2008
)
1.07
"Kynurenic acid (KYNA) is an endogenous compound implicated in the pathophysiology of schizophrenia. "( Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia.
Andersson, AS; Engberg, G; Erhardt, S; Holtze, M; Larsson, K; Linderholm, KR; Nilsson-Todd, LK; Olsson, E; Olsson, SK; Schwieler, L, 2009
)
2.12
"Kynurenic acid (KYNA) is an agonist of the G-protein-coupled receptor GPR35, which is predominantly expressed in gastrointestinal tissues. "( High concentration of kynurenic acid in bile and pancreatic juice.
Fedkiv, O; Paluszkiewicz, P; Piedra, JL; Pierzynowski, SG; Rengman, S; Saran, T; Schabowski, J; Turski, WA; Zgrajka, W, 2009
)
2.11
"Kynurenic acid (KYNA) is a recognized broad-spectrum antagonist of excitatory amino acid receptors with a particularly high affinity for the glycine co-agonist site of the N-methyl-D-aspartate (NMDA) receptor complex. "( Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain--in vitro and ex vivo evidence.
Dekundy, A; Kuc, D; Turski, WA; Zgrajka, W; Zielińska, E, 2009
)
2.05
"Kynurenic acid (KYNA) is a tryptophan metabolite produced in the kynurenine pathway. "( Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells.
Rzeski, W; Turski, WA; Wejksza, K,
)
3.02
"Kynurenic acid is an endogenous product of the tryptophan metabolism, and as a broad-spectrum antagonist of excitatory amino acid receptors may serve as a protective agent in neurological disorders. "( A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study.
Farkas, T; Fülöp, F; Kis, Z; Marosi, M; Nagy, D; Robotka, H; Rózsa, E; Toldi, J; Vécsei, L, 2010
)
2.24
"Kynurenic acid (KYNA) is an endogenous antagonist of the ionotropic glutamate receptors and the α7 nicotinic acetylcholine receptor as well as an agonist of the G-protein-coupled receptor GPR35. "( Distribution, synthesis, and absorption of kynurenic acid in plants.
Bartnik, M; Kocki, T; Turska, M; Turski, MP; Turski, WA; Zgrajka, W, 2011
)
2.07
"Kynurenic acid (KYNA) is an endogenous metabolite of the kynurenine pathway for tryptophan degradation and an antagonist of both N-methyl-D-aspartate (NMDA) and alpha-7 nicotinic acetylcholine (α7nACh) receptors. "( On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress.
Blanco-Ayala, T; Carrillo-Mora, P; García, E; La Cruz, VP; López, T; Lugo-Huitrón, R; Maldonado, PD; Ortiz-Islas, E; Pedraza-Chaverrí, J; Pineda, B; Pinzón, E; Santamaría, A; Silva-Adaya, D; Torres, I; Torres-Ramos, M; Ugalde-Muñiz, P,
)
1.86
"Kynurenic acid (KYNA) is a metabolite of tryptophan which is formed along the kynurenine pathway. "( Potato- an important source of nutritional kynurenic acid.
Kamiński, P; Turska, M; Turski, MP; Turski, WA; Zgrajka, W, 2012
)
2.08
"Kynurenic acid (KYNA) is a neuroactive metabolite of tryptophan that is thought to regulate cognitive functions. "( Elevated cerebrospinal fluid kynurenic acid levels in patients with tick-borne encephalitis.
Atlas, A; Holtze, M; Lindquist, L; Mickiené, A; Schwieler, L, 2012
)
2.11
"Kynurenic acid (KYNA) is a broad-spectrum antagonist at all subtypes of ionotropic glutamate receptors, but is preferentially active at the strychnine-insensitive glycine allosteric site of the N-methyl-D-aspartate (NMDA) receptor and is also a non-competitive antagonist at the alpha7 nicotinic receptor. "( Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor.
Kandefer-Szerszen, M; Kocki, T; Okuno, E; Parada-Turska, J; Rejdak, R; Rzeski, W; Turski, WA; Wejksza, K; Zdzisinska, B; Zrenner, E, 2004
)
3.21
"Kynurenic acid (KYNA) is an endogenous glutamate antagonist with a preferential action at the glycinesite of the N-methyl D-aspartate (NMDA)-receptor."( Kynurenic acid and schizophrenia.
Engberg, G; Erhardt, S; Schwieler, L, 2003
)
2.48
"Kynurenic acid (KYNA) is an astrocyte-derived, endogenous neuroinhibitory compound, which shares several of adenosine's properties."( Neuronal A1 receptors mediate increase in extracellular kynurenic acid after local intrastriatal adenosine infusion.
Fuxe, K; Schwarcz, R; Wu, HQ, 2004
)
1.29
"Kynurenic acid (KYNA) is an endogenous metabolite in the kynurenine pathway of tryptophan degradation and is an antagonist at the glycine site of the N-methyl-D-aspartate as well as at the alpha 7 nicotinic cholinergic receptors. "( Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes.
Baran, H; Ferraz-Leite, H; Kainz, A; Kalina, P; Kepplinger, B; Newcombe, J, 2005
)
2.08
"Kynurenic acid is an antagonist of ionotropic glutamate receptors. "( Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro.
Kandefer-Szerszeń, M; Majdan, M; Parada-Turska, J; Rzeski, W; Turski, W; Zgrajka, W, 2006
)
3.22
"Kynurenic acid (KYNA) is an endogenous glutamate-receptor antagonist with a preferential action at the glycine-site of the NMDA-receptor. "( Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons--possible involvement of endogenous kynurenic acid.
Engberg, G; Erhardt, S; Linderholm, K; Nilsson, L; Schwieler, L, 2006
)
1.98
"Kynurenic acid (KYNA) is a broad spectrum antagonist of ionotropic glutamate receptors, preferentially active at the strychnine-insensitive glycine allosteric site of the N-methyl-D-aspartate (NMDA) receptor, and a noncompetitive antagonist of alpha7 nicotinic receptor. "( Effect of pesticides on kynurenic acid production in rat brain slices.
Borbely, S; Kocki, T; Kuc, D; Saran, T; Turski, WA; Urbańska, EM; Vilagi, I; Zielińska, E, 2005
)
2.08
"Kynurenic acid (KYNA) is a tryptophan metabolite synthesized and released by glia and recently shown to be a non-competitive antagonist of alpha7 nicotinic acetylcholine receptors at physiologically relevant concentrations, and NMDA receptors at higher concentrations. "( Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding.
Bucci, DJ; Chess, AC, 2006
)
2.05
"Kynurenic acid (KYNA) is an endogenous antagonist of alpha7 nicotinic receptors and all ionotropic glutamate receptors. "( Kynurenic acid in human saliva--does it influence oral microflora?
Kuc, D; Parada-Turska, J; Rahnama, M; Rzeski, W; Tomaszewski, T; Turski, WA; Urbanik-Sypniewska, T; Wejksza, K; Wielosz, M,
)
3.02
"Kynurenic acid (KYNA) is a tryptophan metabolite that is synthesized and released by astrocytes and acts as a competitive antagonist of the glycine site of N-methyl-D-aspartate receptors at high concentrations and as a noncompetitive antagonist of the alpha7-nicotinic acetylcholine receptor at low concentrations. "( Elevations of endogenous kynurenic acid produce spatial working memory deficits.
Alling, TE; Bucci, DJ; Chess, AC; Simoni, MK, 2007
)
2.09
"Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl-D-aspartate-receptor."( The kynurenic acid hypothesis of schizophrenia.
Engberg, G; Erhardt, S; Linderholm, K; Nilsson, L; Schwieler, L, 2007
)
1.62
"Kynurenic acid (KYNA) is an endogenous NMDA receptor antagonist as well as a blocker of the alpha7* nicotinic receptor and mounting evidence suggests that the compound participates in the pathophysiology of schizophrenia. "( Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis.
Andersson, A; Engberg, G; Erhardt, S; Linderholm, KR; Olsson, E; Olsson, S; Snodgrass, R, 2007
)
2.01
"Kynurenic acid is an endogenous neuroactive compound whose unbalancing is involved in the pathogenesis and progression of several neurological diseases. "( Crystal structure of human kynurenine aminotransferase II, a drug target for the treatment of schizophrenia.
Garavaglia, S; Montalbano, V; Rizzi, M; Rossi, F; Walsh, MA, 2008
)
1.79
"Kynurenic acid (KYNA) is an endogenous antagonist of ionotropic glutamate receptors and the alpha 7 nicotinic acetylcholine receptor, showing anticonvulsant and neuroprotective activity. "( Presence of kynurenic acid in food and honeybee products.
Kuc, D; Turska, M; Turski, MP; Turski, WA; Zgrajka, W, 2009
)
2.17
"Kynurenic acid is an antagonist of glutamate and alpha-7 nicotinic acetylcholine receptors and an agonist of the G: -protein-coupled receptor GPR35, which is predominantly expressed in immune and gastrointestinal tissues. "( Micromolar concentration of kynurenic acid in rat small intestine.
Kuc, D; Parada-Turska, J; Turski, WA; Urbanik-Sypniewska, T; Zgrajka, W, 2008
)
2.08
"Kynurenic acid is an endogenous product of the tryptophan metabolism. "( The Janus-face kynurenic acid.
Robotka, H; Rózsa, E; Toldi, J; Vécsei, L, 2008
)
2.14
"As kynurenic acid is an endogenous glutamate receptor antagonist whose brain levels are known to increase in conditions associated to cognitive deficits, it is proposed that the putative cognition enhancers tested may act in vivo by relieving the antagonism produced by excessive endogenous kynurenate."( Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors.
Pattarini, R; Pittaluga, A; Raiteri, M, 1995
)
1.08
"Kynurenic acid is an endogenous excitatory amino-acid receptor antagonist with neuroprotective and anticonvulsant properties. "( (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.
Cini, M; Marconi, M; Schwarcz, R; Speciale, C; Varasi, M; Wu, HQ, 1996
)
1.96
"Kynurenic acid (KYNA) is a tryptophan metabolite and represents the only known endogenous compound acting as an antagonist to excitatory amino acid receptors in the mammalian CNS. "( Kynurenic acid and kynurenine aminotransferase in heart.
Amann, G; Baran, H; Lubec, B; Lubec, G, 1997
)
3.18
"Kynurenic acid (KA) is an excitatory amino acid receptor antagonist that is believed to play an important role in a host of diseases of the neuropsychiatric and central nervous system. "( Determination of kynurenic acid by capillary electrophoresis with laser-induced fluorescence detection.
Hansen, DK; Lunte, SM, 1997
)
2.08
"Kynurenic acid is an excitatory amino acid antagonist with preferential activity at the N-methyl-D-aspartate subtype of glutamate receptors. "( Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro.
Goodman, JH; Scharfman, HE, 1998
)
1.99
"1. Kynurenic acid (KYNA) is a kynurenine metabolite and a broad spectrum excitatory amino acid antagonist that has been shown to be neuroprotective in models of cerebral ischemia, when administered exogenously. "( Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia.
Cini, M; Dho, L; Marconi, M; Molinari, A; Post, C; Rosa, B; Salvati, P; Ukmar, G, 1999
)
1.23
"Kynurenic acid (KYNA) is an antagonist of (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors and it blocks the glycine site of the NMDA receptor preferentially (IC50 = 7.9 microM). "( Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices.
Hodgkins, PS; Lee, SC; Scharfman, HE; Schwarcz, R, 1999
)
1.98
"Kynurenic acid is a tryptophan metabolite provided with antagonist activity on ionotropic glutamate and alpha7 nicotinic acetylcholine receptors. "( Presynaptic kynurenate-sensitive receptors inhibit glutamate release.
Attucci, S; Carpenedo, R; Cozzi, A; Galli, A; Moroni, F; Pittaluga, A; Raiteri, M, 2001
)
1.75
"Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor. "( Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.
Blennow, K; Engberg, G; Erhardt, S; Lindström, LH; Nordin, C; Skogh, E, 2001
)
3.2
"Kynurenic acid (KYNA) is an antagonist of ionotropic glutamate receptors, preferentially blocking the glycine-site of the N-methyl-D-aspartate (NMDA) receptor. "( Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid.
Engberg, G; Erhardt, S, 2002
)
1.96
"Kynurenic acid is an endogenously occurring tryptophan metabolite, which, under certain conditions, may accumulate in human tissues. "( Cellular aspects of phototoxic reactions induced by kynurenic acid. I. Establishment of an experimental model utilizing in vitro cultivated cells.
Brunk, U; Wennersten, G, 1977
)
1.95
"Kynurenic acid is an endogenous substance that inhibits EAA receptors and may therefore influence important physiologic and pathologic processes."( Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors.
Beal, MF; During, MJ; Freese, A; Swartz, KJ, 1990
)
1.28
"Kynurenic acid is a broad-spectrum excitatory amino acid (EAA) receptor antagonist which is present in the mammalian central nervous system. "( Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection.
Beal, MF; MacGarvey, U; Matson, WR; Ryan, EA; Swartz, KJ, 1990
)
2.07
"Kynurenic acid is a broad spectrum antagonist at neuroexcitant amino acid receptors in the mammalian brain. "( Kynurenic acid attenuates experimental ulcer formation and basal gastric acid secretion in rats.
Glavin, GB; Pinsky, C, 1989
)
3.16

Effects

ExcerptReferenceRelevance
"Kynurenic acid (KYNA) has well-established protective properties against glutamatergic neurotransmission, which plays an essential role in the activation and sensitization process during some primary headache disorders. "( A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.
Bajtai, A; Bohár, Z; Fejes-Szabó, A; Fülöp, F; Laborc, K; László, AM; Mándity, I; Nagy-Grócz, G; Párdutz, Á; Szatmári, I; Szentirmai, M; Vécsei, L; Veres, G; Zádori, D, 2017
)
2.18

Actions

Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and abnormalities in KYNA levels have been associated with various central nervous system disorders. Lower levels showed a better therapeutic response to escitalopram.

ExcerptReferenceRelevance
"Kynurenic acid was lower in MDD, and lower levels showed a better therapeutic response to escitalopram."( Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
Erabi, H; Fuchikami, M; Kang, D; Kato, TA; Kurata, A; Okada, G; Okamoto, Y; Setoyama, D; Shibasaki, C; Takamura, M; Yamawaki, S; Yoshino, A, 2020
)
2.72
"Kynurenic acid and Gpr35 enhance Pgc-1α1 expression and cellular respiration, and increase the levels of Rgs14 in adipocytes, which leads to enhanced beta-adrenergic receptor signaling."( Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation.
Agudelo, LZ; Berggren, PO; Brodin, P; Bryzgalova, G; Cervenka, I; Correia, JC; Dadvar, S; Ferreira, DMS; Gerhart-Hines, Z; Izadi, M; Jannig, PR; Lakshmikanth, T; Martínez-Redondo, V; Midttun, Ø; Pereira, T; Pettersson-Klein, AT; Porsmyr-Palmertz, M; Ruas, JL; Sustarsic, EG; Ueland, PM, 2018
)
2.64
"Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and abnormalities in KYNA levels have been associated with various central nervous system disorders. "( Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition.
Campbell, BM; Chang, C; Dounay, A; Fonseca, KR; Gernhardt, SS; Horner, W; Li, C; Liras, J; Maurer, TS; Rong, H; Salafia, MA; Sawant-Basak, A; Strick, CA; Tuttle, JB; Verhoest, P; Welch, KA; Zawadzke, LE, 2018
)
2.18

Treatment

Treatment with kynurenic acid (icv) abolished AVP-induced hypothermia but did not affect rise in blood pressure or drop in heart rate and BAT temperature. Pretreatment with ketamine and transection of the perforant path protect major parts of the hippocampal cell layers from quinolinic acid-induced degenerative effects.

ExcerptReferenceRelevance
"Treatment with kynurenic acid did not alter the morphology changes."( [Comparative study of novel therapeutic possibilities in animal experimental model of inflammatory bowel disease].
Boros, M; Erces, D; Ghyczy, M; Kaszaki, J; Kovács, T; Tiszlavicz, L; Tőkés, T; Varga, G; Vécsei, L, 2012
)
0.72
"Treatment with kynurenic acid (icv) abolished AVP-induced hypothermia but did not affect the AVP-evoked rise in blood pressure or drop in heart rate and BAT temperature."( Role of L-glutamate in systemic AVP-induced hypothermia.
Almeida, MC; Branco, LG; Carnio, EC; Paro, FM, 2003
)
0.66
"Co-treatment with kynurenic acid, an antagonist of the facilitating glycine site of the N-methyl-D-aspartate receptor, or with N(G)-nitro-L-arginine, an inhibitor of nitric oxide synthesis, induced a dose-dependent neuroprotective effect."( Glycine antagonist and NO synthase inhibitor protect the developing mouse brain against neonatal excitotoxic lesions.
Bonnier, C; Delpech, A; Evrard, P; Gressens, P; Marret, S; Raymackers, JM, 1999
)
0.63
"Pretreatment with kynurenic acid and ketamine as well as the transection of the perforant path were noted to protect major parts of the hippocampal cell layers from quinolinic acid-induced degenerative effects."( Quinolinate neurotoxicity and glutamatergic structures.
Keilhoff, G; Schmidt, W; Stastný, F; Wolf, G, 1990
)
0.6

Toxicity

ExcerptReferenceRelevance
" The antagonistic properties of kynurenate were dose-dependent: equimolar kynurenate had no effect on quinolinate but attenuated the actions of ibotenate, kainate and NMDA; 2 x equimolar kynurenate had no effect on quinolinate or ibotenate but attenuated the toxicity of kainate and NMDA; and 3 x equimolar kynurenate had no effect on the toxicity of kainate or ibotenate, attenuated the actions of NMDA and abolished the toxic action of quinolinate."( A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.
Clark, AJ; Hastings, MH; Latimer, M; Stone, TW; Winn, P, 1991
)
0.47
" No toxic effect of quisqualate is observed."( Kainate and NMDA toxicity for cultured developing and adult rat spiral ganglion neurons: further evidence for a glutamatergic excitatory neurotransmission at the inner hair cell synapse.
Delrée, P; Lefebvre, PP; Leprince, P; Moonen, G; Rigo, JM; Rogister, B; Weber, T, 1991
)
0.28
" When present during the exposure, 6-cyano-2,3-dihydroxy-7-nitroquinoxaline (CNQX, 10 microM), an antagonist with preferential action on non-N-methyl-D-aspartate receptors, did not prevent this toxic effect of QA."( Quisqualate neurotoxicity: a delayed, CNQX-sensitive process triggered by a CNQX-insensitive mechanism in young rat hippocampal slices.
Garthwaite, G; Garthwaite, J, 1989
)
0.28
" Greatest protection was observed when the antidote was administered between 30 and 90 min after injection of the toxic extract."( Kynurenic acid protects against neurotoxicity and lethality of toxic extracts from contaminated Atlantic coast mussels.
Bose, R; Glavin, GB; Pinsky, C, 1989
)
1.72
" These data suggest that the use of Neten-20 for one year does not lead to adverse metabolic effects analogous to those seen with combination type oral contraceptives."( Low dose injectable contraceptive norethisterone enanthate 20mg monthly - II. Metabolic side effects.
Bamji, MS; Prema, K; Safaya, S, 1981
)
0.26
" In addition, Tat, at similar concentrations, was toxic to human fetal neurons in culture."( Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity.
Brownstone, RM; Geiger, JD; Knudsen, BE; Magnuson, DS; Nath, A, 1995
)
0.29
" Activation of the coagulation system and adverse effects of homocysteine on the endothelium and vessel wall are believed to underlie disease pathogenesis."( Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor.
Arnelle, DR; Choi, YB; D'Emilia, DM; Kim, WK; Kumar, S; Lipton, SA; Rayudu, PV; Stamler, JS, 1997
)
0.3
" Our findings suggest that the toxic effects of MPP+ on dopaminergic terminals are not mediated through a direct interaction with the NMDA subtype of glutamate receptor, but with the AMPA-kainate subtype."( The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.
Cano, J; Machado, A; Merino, M; Vizuete, ML, 1999
)
0.3
" Agonists of the glycine recognition site of NMDA receptors (D-serine and D-alanine) did not have any toxic effect in hippocampal cultures, whereas competitive blockade of the glycine site by 7-chlorokynurenic acid was neuroprotective."( Glycine-induced neurotoxicity in organotypic hippocampal slice cultures.
Barth, A; Barth, L; Newell, DW; Nguyen, LB, 2005
)
0.52
" In this work we investigated the effect that a systemic administration of L-KYN+PROB exerted on the toxic model induced by 6-OHDA in rats."( Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy.
Carrillo-Mora, P; Colín-Barenque, L; García, E; González-Herrera, IG; Pedraza-Chaverrí, J; Pérez-De La Cruz, V; Santamaría, A; Silva-Adaya, D; Villeda-Hernández, J,
)
0.13
" No evidence of a toxic response was recorded."( On the toxicity of kynurenic acid in vivo and in vitro.
Bednarski, J; Jabłoński, M; Marciniak, S; Małaczewska, J; Siwicki, AK; Turski, MP; Turski, WA, 2014
)
0.73

Pharmacokinetics

ExcerptReferenceRelevance
" To obtain pharmacokinetic data, KA-1, KA-2 and KYNA concentrations were measured following KA-1 or KA-2 injection."( A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.
Bajtai, A; Bohár, Z; Fejes-Szabó, A; Fülöp, F; Laborc, K; László, AM; Mándity, I; Nagy-Grócz, G; Párdutz, Á; Szatmári, I; Szentirmai, M; Vécsei, L; Veres, G; Zádori, D, 2017
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
" Since NMDA receptors play a crucial role in trigeminal pain processing, the aim of our experiments was to compare the effects of L-kynurenine (L-KYN) combined with probenecid (PROB) or with 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride alone, a newly synthetized KYNA derivative, on the NTG-induced nNOS expression in the rat TNC."( l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus.
Bohár, Z; Fülöp, F; Párdutz, A; Tajti, J; Toldi, J; Vámos, E; Varga, H; Vécsei, L, 2009
)
0.59
" Moreover, more information can be provided on the evaluation of toxicity of phorate using metabonomics combined with clinical chemistry."( Metabonomics evaluation of urine from rats administered with phorate under long-term and low-level exposure by ultra-performance liquid chromatography-mass spectrometry.
Guo, L; Hou, Y; Sun, C; Sun, X; Xu, W; Zeng, Y; Zhao, X, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
") did not affect cGMP responses, suggesting poor bioavailability in brain."( Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization.
Cler, JA; Cordi, AA; Dappen, MS; Emmett, MR; Gray, NM; Iyengar, S; Mick, SJ; Monahan, JB; Rao, TS; Wood, PL, 1993
)
0.29
" This stimulation induces indoleamine 2,3-dioxygenase (IDO), an enzyme that reduces the tryptophan bioavailability to synthesize serotonin."( Chronic Mild Stress Alters Kynurenine Pathways Changing the Glutamate Neurotransmission in Frontal Cortex of Rats.
Caso, JR; García-Bueno, B; Leza, JC; Madrigal, JLM; Martín-Hernández, D; Tendilla-Beltrán, H, 2019
)
0.51
" It involves multiple pathways including interference with the bioavailability of tryptophan central to the synthesis of the neurotransmitter serotonin."( Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies.
Arnone, D; Dantzer, R; Salem, H; Saraykar, S; Selvaraj, S; Teixeira, AL, 2018
)
0.48
"6-Hydroxykynurenic acid (6-HKA) is an organic acid component in extracts of Ginkgo biloba leaves and acts as a major contributor to neurorestorative effects, while its oral bioavailability was low."( Pharmacokinetics and brain distribution studies of 6-hydroxykynurenic acid and its structural modified compounds.
He, K; Hu, H; Lou, Y; Ou, F; Pan, J; Shen, Z; Wang, R; Xu, M; Yao, J; Zeng, K; Zeng, S, 2022
)
1.38
"The results illustrated that esterification can greatly improve the apparent permeability coefficient and bioavailability of 6-HKA."( Pharmacokinetics and brain distribution studies of 6-hydroxykynurenic acid and its structural modified compounds.
He, K; Hu, H; Lou, Y; Ou, F; Pan, J; Shen, Z; Wang, R; Xu, M; Yao, J; Zeng, K; Zeng, S, 2022
)
0.96
"The bioavailability and the brain content of 6-HKA can be improved by the prodrug method."( Pharmacokinetics and brain distribution studies of 6-hydroxykynurenic acid and its structural modified compounds.
He, K; Hu, H; Lou, Y; Ou, F; Pan, J; Shen, Z; Wang, R; Xu, M; Yao, J; Zeng, K; Zeng, S, 2022
)
0.96
"Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach."( Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A; Urbanska, EM, 2022
)
2.16
" A 50 mg KYNA/kg/day dosage was orally administered in formulations showing a higher bioavailability when the nutraceutical was complexed with βNS-CDI compared to HPβ-CD and free KYNA, respectively."( Oral supplementation of solvent-free kynurenic acid/cyclodextrin nanosponges complexes increased its bioavailability.
Caldera, F; Cavalli, R; Mahmoudian, M; Matencio, A; Monfared, YK; Pedrazzo, AR; Trotta, F; Valizadeh, H; Zakeri-Milani, P, 2023
)
1.18

Dosage Studied

Kynurenic acid blocks the neurotransmission of the B-J reflex in the NTS. The effect could be blocked by a nonconvulsive dosage of kainic acid. Smaller doses of kynureNic acid are required in SAD rats than in SO rats.

ExcerptRelevanceReference
" The double-blind study with 76 asthmatic children followed for five months indicated significant improvement in asthma following pyridoxine therapy (200 mg daily) and reduction in dosage of bronchodilators and cortisone."( Pyridoxine treatment of childhood bronchial asthma.
Collipp, PJ; Goldzier, S; Snyder, R; Soleymani, Y; Weiss, N, 1975
)
0.25
" In dose-response studies, ifenprodil attenuated the NMDA-induced increase in medium GABA at all ages tested with an Imax of 10 microM."( Developmental differences in antagonism of NMDA toxicity by the polyamine site antagonist ifenprodil.
Nicklas, WJ; Zeevalk, GD, 1992
)
0.28
" DTT treatment also markedly shifted the dose-response curve of NMDA to the left."( Redox modulation of N-methyl-D-aspartate-stimulated neurotransmitter release from rat brain slices.
Blair, R; Woodward, JJ, 1991
)
0.28
" Analysis of dose-response curves for the action of glycine on responses to 100 microM-NMDA revealed a 3-fold higher potency of glycine for potentiation of peak versus steady-state responses, with concentrations for half-activation of 134 and 382 nM, respectively."( Modulation of N-methyl-D-aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurones.
Benveniste, M; Mayer, ML; Vyklický, L, 1990
)
0.28
" As in the in vitro experiments, the dose-response curve for the antagonist was shifted rightward in a parallel fashion when D-serine was coinjected."( Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site.
Baron, BM; Harrison, BL; McDonald, IA; Miller, FP; Palfreyman, MG; Salituro, FG; Schmidt, CJ; Sorensen, SM; White, HS, 1990
)
0.59
" Their respective dose-response curves had a similar maximum but the slope of the curve for AMPA was consistently steeper than that for quisqualate."( The pharmacology of quisqualate and AMPA in the cerebral cortex of the rat in vitro.
Horne, AL; Simmonds, MA, 1989
)
0.28
" Dose-response studies demonstrated that the synaptic input to NTS units was substantially blocked by 2-amino-5-phosphonovaleric acid (APV) at perfusion concentrations of 1 mM, by kynurenic acid (KYN) at 10 mM, and glutamate diethylester (GDEE) at 10 mM."( Excitatory amino acid receptors intrinsic to synaptic transmission in nucleus tractus solitarii.
Felder, RB; Miller, BD, 1988
)
0.47
" Kynurenate and the piperazine derivatives blocked up to 80% of the synaptic response at doses of 1000 microM, with single-affinity dose-response curves."( Antagonism of lateral olfactory tract synaptic potentials in rat prepyriform cortex slices.
Cotman, CW; Ganong, AH; Hearn, TJ, 1986
)
0.27
" In rats there is no ratio between the dosage used and the levels of the metabolites excreted."( Effects of two different loading doses of L-tryptophan on the urinary excretion of tryptophan metabolites in rats, mice and guinea pigs. Correlation with the enzyme activities.
Allegri, G; Baccichetti, F; Biasiolo, M; Costa, C,
)
0.13
" The effect of kynurenic acid could be blocked by a nonconvulsive dosage of kainic acid."( The WAG/Rij rat model for nonconvulsive absence epilepsy: involvement of nonNMDA receptors.
Coenen, AM; Peeters, BW; Ramakers, GM; Vossen, JM, 1994
)
0.64
" Pretreatment with glycine, an agonist to the glycine/NMDA receptors, shifted the dose-response effect of felbamate to the right (ED50 = 56."( Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
Aguglia, U; Bertorelli, R; De Sarro, A; De Sarro, G; Ongini, E, 1994
)
0.29
" The dose-response effects of glutamate and serine were studied on the population spikes evoked in the granular cell layer."( Serine released from hippocampal slices during deprivation of oxygen and glucose enhances the effects of glutamate on neuronal function.
Hirai, H; Okada, Y, 1993
)
0.29
" The time course and dose-response relationships for this effect were examined after treatment with two representative antidepressant drugs (imipramine and citalopram) and electriconvulsive shock (ECS)."( Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments.
Layer, RT; Nowak, G; Paul, IA; Popik, P; Skolnick, P, 1994
)
0.29
" Comparison of the effect of kynurenic acid on the hypotension and bradycardic dose-response curves showed a significant difference between SO and SAD rats, indicating that smaller doses of kynurenic acid are required in SAD rats than in SO rats to block the neurotransmission of the B-J reflex in the NTS."( Neurotransmission of the Bezold-Jarisch reflex in the nucleus tractus solitarii of sino-aortic deafferentated rats.
Bonagamba, LG; Chianca, DA; Machado, BH, 1997
)
0.59
" Even though the endogenous levels of KA in rat brain are below this limit of detection, this methodology could be used to monitor the increase of KA levels in rat brain following dosing with its precursors, tryptophan and kynurenine."( Determination of kynurenic acid by capillary electrophoresis with laser-induced fluorescence detection.
Hansen, DK; Lunte, SM, 1997
)
0.64
"Chronic dosing with the glycine partial NMDA agonist, 1-aminocyclopropanecarboxylic acid (ACPC) elicited an altered allosteric regulation of cortical NMDA receptor binding."( Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.
Boje, KM; Lakhman, SS, 1998
)
0.3
" Coupled with our previous in vitro demonstration of bicarbonate-dependent organic cation transport, the present study suggests that bicarbonate inhibition of renal tubule organic cation secretion may explain the previous observation that bicarbonate dosing decreases amantadine excretion by the kidney."( In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport.
Goralski, KB; Sitar, DS; Smyth, DD, 1999
)
0.3
" N-Methyl-D-aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam resulting in a bell-shaped dose-response curve."( Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003
)
0.32
" However, co-administration of these antagonists with morphine into the vPAG enhanced the acute antinociceptive effects of morphine as measured by a leftward shift in the morphine dose-response curves."( Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat.
Bobeck, EN; Ingram, SL; Morgan, MM, 2009
)
0.35
" As it did not induce any appreciable side-effect at the protective dose applied in a chronic dosing regime in this mouse model, it appears worthy of further thorough investigations with a view to eventual clinical trials."( Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.
Freund, TF; Fülöp, F; Klivényi, P; Nyiri, G; Szatmári, I; Szonyi, A; Toldi, J; Vécsei, L; Zádori, D, 2011
)
0.65
" In mouse hippocampal slices, sunifiram at 10-100 nM significantly enhanced LTP in a bell-shaped dose-response relationship which peaked at 10 nM."( Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor.
Fukunaga, K; Moriguchi, S; Narahashi, T; Tanaka, T, 2013
)
0.39
" Dose-response curves were constructed and the values of ED50 for treatment alone and combined were statistically compared."( Synergistic effect of the L-tryptophan and kynurenic acid with dipyrone or paracetamol in mice.
Carvalho, AM; de França Fonteles, MM; de Sousa, FC; Dias, ML; Freire, LV; Rios, ER; Rocha, NF, 2013
)
0.65
" This in vivo study on anesthetized rats therefore tested the effects of the administration of KYNA and a KYNA derivative (SZR72) (in a dosage that exerted neuroprotection) on long-term potentiation (LTP) and pure field excitatory postsynaptic potentials induced by contralateral CA3 region stimulation and recorded in the pyramidal layer of the CA1 region of the hippocampus."( Paradox effects of kynurenines on LTP induction in the Wistar rat. An in vivo study.
Demeter, I; Farkas, T; Fülöp, F; Gellert, L; Kis, Z; Knapp, L; Kocsis, K; Nagy, K; Toldi, J; Vecsei, L, 2013
)
0.39
" In the first series we determined the dose-response and time course effects of intrathecally administered KYNA (10-100 μg), D-(-)-2-amino-5-phosphonopentanoic acid (AP5; an NMDA receptor antagonist; 10-200 μg), methyllycaconitine (MLA; an alpha 7 nicotinic receptor antagonist; 100-200 μg) and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzoquinoxaline-7-sulfonamide (NBQX; an AMPA/kainate receptor antagonist; 1-20 μg)."( The inimitable kynurenic acid: the roles of different ionotropic receptors in the action of kynurenic acid at a spinal level.
Bohar, Z; Horvath, G; Kekesi, G; Pardutz, A; Petrovszki, Z; Safrany-Fark, A; Tar, L; Tuboly, G; Vecsei, L, 2015
)
0.77
" However, using a comprehensive panel of behavioral tests, we demonstrate that the chronic dosing of a selective KMO inhibitor does not significantly modify behavioral phenotypes or natural progression in mouse models of HD."( The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Beaumont, V; Bradaia, A; Deisemann, H; Dijkman, U; Dominguez, C; Ebneth, A; Freije, R; Gelman, S; Gleyzes, M; Heikkinen, T; Heins, M; Javier, RM; Khetarpal, V; Kontkanen, O; Lehtimäki, K; Mrzljak, L; Munoz-Sanjuan, I; Neagoe, I; Park, LC; Puoliväli, J; Rassoulpour, A; Steidl, E; Toledo-Sherman, L; Tombaugh, G; Winkler, D, 2016
)
0.43
" A 50 mg KYNA/kg/day dosage was orally administered in formulations showing a higher bioavailability when the nutraceutical was complexed with βNS-CDI compared to HPβ-CD and free KYNA, respectively."( Oral supplementation of solvent-free kynurenic acid/cyclodextrin nanosponges complexes increased its bioavailability.
Caldera, F; Cavalli, R; Mahmoudian, M; Matencio, A; Monfared, YK; Pedrazzo, AR; Trotta, F; Valizadeh, H; Zakeri-Milani, P, 2023
)
1.18
" Renal and biliary excretions and plasma concentration-time profiles of KYNA, pyridoxic acid (PDA), homovanillic acid (HVA), and coproporphyrin I (CP-I) were assessed in BDC monkeys dosed with either probenecid (PROB) at 100 mg/kg or the control vehicle."( Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys.
Hao, J; Lai, Y; Liu, R; Zhao, X, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
G-protein-coupled receptor agonistAn agonist that binds to and activates G-protein-coupled receptors
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
nicotinic antagonistAn antagonist at the nicotinic cholinergic receptor.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
quinolinemonocarboxylic acidAny aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
monohydroxyquinolineA hydroxyquinoline carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Tryptophan catabolism1426
Signaling Pathways1269117
Signaling by GPCR24955
GPCR ligand binding19339
Class A/1 (Rhodopsin-like receptors)16136
Tryptophan Metabolism1855
Kynurenine pathway and links to cell senescence2024
Biochemical pathways: part I0466
Tryptophan metabolism2342

Protein Targets (64)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency22.40390.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency27.14450.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency27.14450.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.41810.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency0.05800.000811.382244.6684AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
ParkinHomo sapiens (human)Potency1.83560.819914.830644.6684AID720573
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
alpha-galactosidaseHomo sapiens (human)Potency8.91254.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.66750.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency0.25120.036619.637650.1187AID2112
cytochrome P450 2C19 precursorHomo sapiens (human)Potency19.95260.00255.840031.6228AID899
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.90080.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency0.04740.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency50.11870.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency0.32640.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.00890.031622.3146100.0000AID588579
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.01780.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mitogen-activated protein kinase 13Homo sapiens (human)Ki1,300.00000.00080.00080.0008AID216241
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)IC50 (µMol)15.00000.00401.73519.8000AID754130
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)IC50 (µMol)15.00000.00401.65799.8000AID754130
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)2,900.00000.00011.14948.0000AID754131
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)IC50 (µMol)2,900.00000.00011.03936.0000AID754131
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)101.00000.00011.617910.0000AID92493
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)101.00000.00011.700010.0000AID92493
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)101.00000.00011.700010.0000AID92493
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)101.00000.00011.700010.0000AID92493
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00700.98217.0000AID93717
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)IC50 (µMol)2,900.00000.00011.30188.0000AID754131
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)IC50 (µMol)2,900.00000.00010.98006.0000AID754131
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)2,900.00000.00011.19936.0000AID754131
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)98.04000.00071.600310.0000AID143167; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki5.40000.00030.86666.6900AID143299
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)IC50 (µMol)7.00000.00204.15279.9000AID754129
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)2,900.00000.00011.02016.0000AID754131
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)2,900.00000.00010.93746.0000AID754131
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)2,900.00000.00011.01936.0000AID754131
Mitogen-activated protein kinase 12Homo sapiens (human)Ki1,300.00000.00080.00080.0008AID216241
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)112.50000.00071.630610.0000AID144895; AID144896; AID145260
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)112.50000.00061.525710.0000AID144895; AID144896; AID145260
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)112.50000.00071.747210.0000AID144895; AID144896; AID145260
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)IC50 (µMol)15.00000.00101.88779.8000AID754130
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)IC50 (µMol)15.00000.00101.99589.8000AID754130
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)IC50 (µMol)15.00000.00401.33259.8000AID754130
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)IC50 (µMol)15.00000.00401.86339.8000AID754130
Mitogen-activated protein kinase 11Homo sapiens (human)Ki1,300.00000.00080.05580.2200AID216241
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)IC50 (µMol)2,900.00000.00011.02016.0000AID754131
Mitogen-activated protein kinase 14Homo sapiens (human)Ki1,300.00000.00010.07490.3100AID216241
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)112.50000.00071.741110.0000AID144895; AID144896; AID145260
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Vesicular glutamate transporter 3Rattus norvegicus (Norway rat)Ki1,300.00000.04000.11500.1900AID216241
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)IC50 (µMol)15.00000.00401.65799.8000AID754130
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)112.50000.00071.741110.0000AID144895; AID144896; AID145260
G-protein coupled receptor 35Homo sapiens (human)IC50 (µMol)39.00000.03001.39804.6600AID1433846
G-protein coupled receptor 35Homo sapiens (human)Ki137.00000.01152.44679.8600AID769725
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)112.50000.00071.741110.0000AID144895; AID144896; AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aryl hydrocarbon receptorHomo sapiens (human)EC50 (µMol)0.30000.00151.976910.0000AID754127
G protein-coupled receptor GPR35Rattus norvegicus (Norway rat)EC50 (µMol)66.00000.06110.38070.9860AID754143
G-protein coupled receptor 35Homo sapiens (human)EC50 (µMol)199.80000.00202.50079.8000AID1460079; AID1460080; AID1775493; AID1775494; AID665256; AID665260; AID754149; AID769739; AID769741
Histamine H3 receptorRattus norvegicus (Norway rat)EC50 (µMol)500.00000.00201.55926.2000AID665260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Kb137.00000.59003.33007.0000AID163310; AID187000
Glutamate receptor 2Rattus norvegicus (Norway rat)Kb137.00000.59003.17337.0000AID163310; AID187000
Glutamate receptor 3Rattus norvegicus (Norway rat)Kb137.00000.59003.17787.0000AID163310; AID187000
Glutamate receptor 4Rattus norvegicus (Norway rat)Kb137.00000.59003.28567.0000AID163310; AID187000
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Kb89.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kb154.00000.00592.09697.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)Kb89.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Kb89.00001.29004.04509.0000AID91453
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kb154.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kb154.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kb154.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)Kb89.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kb154.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)Kb89.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kb154.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kb154.00000.00592.41137.0000AID143250; AID145182; AID187000
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (214)

Processvia Protein(s)Taxonomy
response to osmotic stressMitogen-activated protein kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of interleukin-6 productionMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to UVMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of inflammatory responseMitogen-activated protein kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sorbitolMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to anisomycinMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sodium arseniteMitogen-activated protein kinase 13Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 13Homo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
adult locomotory behaviorGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of sensory perception of painGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
cellular response to L-glutamateGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
protein insertion into membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of calcium ion transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
blood vessel developmentAryl hydrocarbon receptorHomo sapiens (human)
regulation of adaptive immune responseAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of T cell mediated immune response to tumor cellAryl hydrocarbon receptorHomo sapiens (human)
regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
xenobiotic metabolic processAryl hydrocarbon receptorHomo sapiens (human)
apoptotic processAryl hydrocarbon receptorHomo sapiens (human)
response to xenobiotic stimulusAryl hydrocarbon receptorHomo sapiens (human)
response to toxic substanceAryl hydrocarbon receptorHomo sapiens (human)
regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
cAMP-mediated signalingAryl hydrocarbon receptorHomo sapiens (human)
intracellular receptor signaling pathwayAryl hydrocarbon receptorHomo sapiens (human)
regulation of B cell proliferationAryl hydrocarbon receptorHomo sapiens (human)
circadian regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of inflammatory responseAryl hydrocarbon receptorHomo sapiens (human)
cellular response to molecule of bacterial originAryl hydrocarbon receptorHomo sapiens (human)
cellular response to cAMPAryl hydrocarbon receptorHomo sapiens (human)
cellular response to forskolinAryl hydrocarbon receptorHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxineAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein phosphorylationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
intracellular calcium ion homeostasisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
learning or memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
short-term memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of cell population proliferationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of MAPK cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of angiogenesisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapse organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
sensory processingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein metabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendritic spine organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
modulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendrite arborizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of long-term synaptic potentiationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid precursor protein catabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to amyloid-betaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid fibril formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of CoA-transferase activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 12Homo sapiens (human)
signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
muscle organ developmentMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of peptidase activityMitogen-activated protein kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 12Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 12Homo sapiens (human)
myoblast differentiationMitogen-activated protein kinase 12Homo sapiens (human)
negative regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 12Homo sapiens (human)
regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
neuromuscular process controlling balanceGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 11Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 11Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
bone developmentMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 11Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 11Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 11Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 11Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
calcium ion transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
dendrite developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
rhythmic processGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
prepulse inhibitionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
negative regulation of dendritic spine developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
cytoskeleton organizationG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationG-protein coupled receptor 35Homo sapiens (human)
chemokine-mediated signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityG-protein coupled receptor 35Homo sapiens (human)
negative regulation of neuronal action potentialG-protein coupled receptor 35Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 35Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
voltage-gated monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
neurotransmitter receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
transcription cis-regulatory region bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAryl hydrocarbon receptorHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
TFIID-class transcription factor complex bindingAryl hydrocarbon receptorHomo sapiens (human)
transcription coactivator bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activityAryl hydrocarbon receptorHomo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
protein bindingAryl hydrocarbon receptorHomo sapiens (human)
TBP-class protein bindingAryl hydrocarbon receptorHomo sapiens (human)
protein homodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
protein heterodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
Hsp90 protein bindingAryl hydrocarbon receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAryl hydrocarbon receptorHomo sapiens (human)
E-box bindingAryl hydrocarbon receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
amyloid-beta bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
toxic substance bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chloride channel regulator activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein homodimerization activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
identical protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein phosphatase 2A bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 35Homo sapiens (human)
C-X-C chemokine receptor activityG-protein coupled receptor 35Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (61)

Processvia Protein(s)Taxonomy
cytosolMitogen-activated protein kinase 13Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 13Homo sapiens (human)
nucleusMitogen-activated protein kinase 13Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
presynaptic active zone membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nuclear aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nucleoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytosolAryl hydrocarbon receptorHomo sapiens (human)
chromatinAryl hydrocarbon receptorHomo sapiens (human)
transcription regulator complexAryl hydrocarbon receptorHomo sapiens (human)
protein-containing complexAryl hydrocarbon receptorHomo sapiens (human)
cytosolic aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 12Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase 12Homo sapiens (human)
nucleusMitogen-activated protein kinase 12Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 12Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
nucleoplasmMitogen-activated protein kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase 11Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 11Homo sapiens (human)
nucleusMitogen-activated protein kinase 11Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
plasma membraneG-protein coupled receptor 35Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (117)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID112661In vivo antagonist activity against seizures elicited by audiogenic administered intra peritoneally in mice1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID683586Antibacterial activity against Bacillus subtilis after 20 hrs by tube dilution method2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID769722Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells at 100 uM after 90 mins by beta-arrestin recruitment assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID143618Ability to compete with [3H]glycine for strychnine-insensitive binding sites on rat cortical and hippocampal membrane1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID754149Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID144181Apparent dissociation constant of [3H]glycine from N-methyl-D-aspartate glutamate receptor in rat cortical slice preparation expressed as log values.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID1133431Antiallergic activity in egg albumin-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis compound administered ip 5 mins prior to egg albumin and Evans blue dye challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Antiallergic activity of tetracyclic derivatives of quinoline-2-carboxylic acids. 1.
AID144896Inhibition of [3H]glycine binding to glycine site of N-methyl-D-aspartate glutamate receptor in rat cortical membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID683574Inhibition of bocillin FL binding to PBP 4 in Escherichia coli MM 294 membrane preparation by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID216241Compound was evaluated for the inhibition of Vesicular glutamate transporter (VGLUT)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport.
AID144895Inhibition of [3H]-glutamate binding to N-methyl-D-aspartate glutamate receptor of rat cortical membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID143299Ability to displace strychnine-insensitive [3H]glycine binding to rat cortical membranes.1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
3-Phenyl-4-hydroxyquinolin-2(1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex.
AID769741Agonist activity at human GPR35 by DMR assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID143163Concentration required to inhibit 50% of the specific binding of [3H]glycine to NMDA receptor prepared from rat cerebral cortex and hippocampus1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
2-Carboxytetrahydroquinolines. Conformational and stereochemical requirements for antagonism of the glycine site on the NMDA receptor.
AID399785Antibacterial activity against Escherichia coli by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID1775493Agonist activity at human GPR35 receptor by beta-arrestin assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives as Human G Protein-Coupled Receptor-35 (hGPR35) Agonists and a Consequent New Design Principle.
AID683570Inhibition of bocillin FL binding to PBP 2 in Escherichia coli MM 294 membrane preparation by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID683577Inhibition of bocillin FL binding to PBP 5/6 in Escherichia coli MM 294 membrane preparation at 1 mM by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID1460080Agonist activity at human GPR35 expressed in CHO-K1 cells after 90 mins by beta-arrestin 2 recruitment assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists.
AID754129Inhibition of alpha7 nAChR (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID399789Antibacterial activity against Bacillus subtilis by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID163310Apparent dissociation constant of [3H]AMPA from quisqualate receptor of rat cortical slice1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID769739Agonist activity at human GPR35 expressed in CHO cells assessed as increase in intracellular Ca2+ measured over 20 secs by Aequorin assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID227647Activity was determined by inhibition of glutamate stimulated accumulation of cyclic GMP in neonatal rat cerebral slices.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID143790Ability to compete with [3H]CCP for rat cortical and hippocampal membrane glutamate binding site.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID1494470Inhibition of Rickettsia prowazekii N-terminal His6-tagged methionine aminopeptidase 1 expressed in Escherichia coli DLB3 Rosetta cells at 10 uM using Met-AMC as substrate preincubated for 1 hr followed by 30 mins incubation after substrate addition measu2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
The identification of inhibitory compounds of Rickettsia prowazekii methionine aminopeptidase for antibacterial applications.
AID399784Antibacterial activity against Enterobacter cloacae by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID754132Inhibition of AMPA receptor (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID683581Inhibition of bocillin FL binding to Escherichia coli MM 294 PBP by whole-cell assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID145182Apparent dissociation constant of [3H]glycine from N-methyl-D-aspartate glutamate receptor in rat cortical slice preparation1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID769725Displacement of [3H]PSB-13253 from human recombinant GPR35 exprssed in CHO cells by liquid scintillation counting analysis2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
6-Bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic Acid: a powerful tool for studying orphan G protein-coupled receptor GPR35.
AID665256Agonist activity at GPR35 in human HT-29 cells by dynamic mass redistribution assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists.
AID399787Antibacterial activity against Shigella flexneri by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID229653Selectivity ratio as the ratio of IC50 values for [3H]CPP/[3H]-gly1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID143781Activity against rat cortical and hippocampal membrane N-methyl-D-aspartate glutamate receptor 1/2A/2B/2C/2D using [3H]CPP1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID754131Inhibition of GABAA receptor (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID1133432Antiallergic activity in egg albumin-sensitized Sprague-Dawley rat assessed as inhibition of passive cutaneous anaphylaxis at 25 to 50 mg/kg, po administered 15 mins prior to egg albumin and Evans blue dye challenge1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Antiallergic activity of tetracyclic derivatives of quinoline-2-carboxylic acids. 1.
AID683585Inhibition of bocillin FL binding to Bacillus subtilis PBP5 at 1 mM by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID113249Antagonist activity in audiogenic seizure model in vivo through icv route1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID683584Inhibition of bocillin FL binding to Bacillus subtilis PBP3/4 at 1 mM by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID187000Functional antagonistic potency assessed by determination of the apparent dissociation constant for antagonism of the depolarizations induced by NMDA and AMPA in rat cortical slice preparation1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
2-Carboxytetrahydroquinolines. Conformational and stereochemical requirements for antagonism of the glycine site on the NMDA receptor.
AID665260Agonist activity at GPR35 in human U20S cells expressing beta-lactamase and Gal4-VP16 transcription factor assessed as beta arrestin translocation after 5 hrs by Tango assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists.
AID147190Inhibition of [125I]- NGF binding to extracellular domain of p75 receptor; IA=Inactive1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor.
AID1433846Antagonist activity at GPR35 (unknown origin)2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Structure-activity relationships of benzothiazole GPR35 antagonists.
AID665266Agonist activity at GPR35 in human U2OS cells expressing beta-lactamase and Gal4-VP16 transcription factor assessed as beta arrestin translocation after 5 hrs by Tango assay relative to zaprinast2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID399788Antibacterial activity against Staphylococcus aureus by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID1133374Antiallergic activity in iv dosed Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity correlations for a series of antiallergy agents. Oxanilic, quinaldic, and benzopyran-2-carboxylic acids.
AID638452Antiexcitatory activity in rat hippocampus pyramidal CA1 region assessed as reduction in field excitatory postsynaptic potential at 16 uM by electrophysiologic method2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Synthesis and biological effects of some kynurenic acid analogs.
AID399786Antibacterial activity against Proteus mirabilis by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID665265Agonist activity at GPR35 in human HT-29 cells by dynamic mass redistribution assay relative to zaprinast2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Thieno[3,2-b]thiophene-2-carboxylic acid derivatives as GPR35 agonists.
AID683582Inhibition of bocillin FL binding to Bacillus subtilis PBP1 at 1 mM by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID144467Binding activity against N-methyl-D-aspartate glutamate receptor in rat brain homogenate using [3H]CPP as the radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID92493Inhibition of [3H]-AMPA binding to AMPA receptor of rat cortical membrane1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID91453Apparent dissociation constant of [3H]kainate from Ionotropic glutamate receptor ionotropic kainate was determined in rat cortical slice preparation1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID399783Antibacterial activity against Pseudomonas aeruginosa by disk diffusion method1998Journal of natural products, Feb, Volume: 61, Issue:2
Transtorine, a new quinoline alkaloid from Ephedra transitoria.
AID1775494Agonist activity at human GPR35 receptor by DMR assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives as Human G Protein-Coupled Receptor-35 (hGPR35) Agonists and a Consequent New Design Principle.
AID754127Activation of AHR (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID143250In vitro inhibition of cortical slice at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID754143Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID144468Binding activity against N-methyl-D-aspartate glutamate receptor in rat brain homogenate using [3H]-glycine as the radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID93717Inhibition of [3H]-kainic acid binding to kainate receptor of rat cortical membrane1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID754130Inhibition of NMDA receptor (unknown origin)2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
AID143472Activity against rat cortical and hippocampal membrane strychnine-insensitive N-methyl-D-aspartate glutamate receptor 1 using [3H]-gly1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID683583Inhibition of bocillin FL binding to Bacillus subtilis PBP2 at 1 mM by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID1460079Agonist activity at human GPR35 expressed in CHO-K1 cells by DMR assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists.
AID234200Ratio of the inhibitory activity against [3H]-CCP for rat cortical and hippocampal membrane glutamate binding site to [3H]glycine for rat cortical and hippocampal membrane binding site.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID143765Selectivity ratio for CPP and gly NMDA binding1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID683568Inhibition of bocillin FL binding to PBP 1a/1b in Escherichia coli MM 294 membrane preparation by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID143167Inhibition of [3H]-MK-801 binding to a N-methyl-D-aspartic acid(NMDA) receptor in glycine-sensitive rat cortical membranes.1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
3-Phenyl-4-hydroxyquinolin-2(1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex.
AID74835Inhibitory activity against vesicular glutamate transport (GVT) in synaptic vesicles isolated from rat forebrain1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Quinoline-2,4-dicarboxylic acids: synthesis and evaluation as inhibitors of the glutamate vesicular transport system.
AID683580Antibacterial activity against Escherichia coli MM 294 after 20 hrs by tube dilution method2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID683572Inhibition of bocillin FL binding to PBP 3 in Escherichia coli MM 294 membrane preparation by gel electrophoresis2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
4-quinolones as noncovalent inhibitors of high molecular mass penicillin-binding proteins.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345072Rat GPR35 (Class A Orphans)2006The Journal of biological chemistry, Aug-04, Volume: 281, Issue:31
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
AID1345073Human GPR35 (Class A Orphans)2013Journal of biomolecular screening, Jun, Volume: 18, Issue:5
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
AID1345073Human GPR35 (Class A Orphans)2006The Journal of biological chemistry, Aug-04, Volume: 281, Issue:31
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
AID1345058Mouse GPR35 (Class A Orphans)2006The Journal of biological chemistry, Aug-04, Volume: 281, Issue:31
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID493017Wombat Data for BeliefDocking1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
3-Phenyl-4-hydroxyquinolin-2(1H)-ones: potent and selective antagonists at the strychnine-insensitive glycine site on the N-methyl-D-aspartate receptor complex.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,534)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990448 (17.68)18.7374
1990's775 (30.58)18.2507
2000's519 (20.48)29.6817
2010's546 (21.55)24.3611
2020's246 (9.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.76 (24.57)
Research Supply Index7.88 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index83.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (1.07%)5.53%
Reviews118 (4.52%)6.00%
Case Studies4 (0.15%)4.05%
Observational4 (0.15%)0.25%
Other2,457 (94.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Safety of Topically Delivered FS2 in Humans. Phase 1 Clinical Trial [NCT02340325]Phase 120 participants (Actual)Interventional2015-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]